GlassScriptPhysician profile
Chad Gordon
NPI 1952583932
$2,871,026.65
in general payments reported to CMS, 2019-2025
11 companies · $286K in 2025
The $286K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $157K · 2021: $306K · 2022: $798K · 2023: $525K · 2024: $636K · 2025: $286K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $730K · Royalty Or License: $714K · Food and Beverage: $1,459 · Travel and Lodging: $1,374 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $729,701.00 |
| Royalty Or License | $713,842.86 |
| Food and Beverage | $1,458.91 |
| Travel and Lodging | $1,373.56 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranius LLC | $1,315,784.37 | 2022-2024 | |
| Stryker Corporation | $1,118,743.63 | 2019-2025 | Na, Universal Neuro 3, Vsp System, Vsp Cranial |
| Osteomed LLC | $251,826.64 | 2019-2022 | |
| Longeviti Neuro Solutions INC | $108,569.89 | 2019-2021 | |
| Medical Device Business Services, INC. | $59,564.81 | 2019-2025 | Na, Cranioplastic |
| Acumed LLC | $12,522.84 | 2022-2024 | Osteomed |
| Medtronic USA, INC. | $2,700.00 | 2020 | |
| Depuy Synthes Sales INC. | $751.83 | 2020-2025 | Matrixneuro, Trumatch, Synthecel |
| Synthes Gmbh | $250.00 | 2023 | |
| Synthes USA Products LLC | $174.75 | 2024-2025 | Trumatch |
| Ethicon US, LLC | $137.89 | 2023 | Evarrest, Surgiflo Hemostatic Matrix, Vistaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,056,800.12 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.